HOME >> BIOLOGY >> NEWS
Scientists find hormone activity explains adolescent mood swings

The "raging hormones" of puberty are known to produce mood swings and stress for most teenagers, making it difficult to cope with this period of life. Until now, the specific causes of pubertal anxiety have not been identified, making it harder to understand and treat adolescent angst.

In the current edition of the journal Nature Neuroscience, researchers led by Sheryl S. Smith, PhD, professor of physiology and pharmacology at SUNY Downstate Medical Center, report findings demonstrating that a hormone normally released in response to stress, THP, actually reverses its effect at puberty, when it increases anxiety.

This hormone normally acts like a tranquilizer, acting at sites in the brain that "calm" brain activity. In the adult, this stress hormone helps the individual adapt to stress, with a calming effect produced half an hour after the event.

Specifically, the GABA-A receptor is the target for steroids, such as THP (or allopregnanolone), which reduce anxiety. GABA-A receptors calm activity in the brain. As such, they are the targets for most sedative, tranquilizing drugs.

One sub-type, GABA-A receptors containing the delta subunit, such as alpha4-beta2-delta, has the highest sensitivity to steroids. In order to study its role in puberty, the researchers used a mouse model that reliably predicts the human condition. In this rodent model, the alpha4-beta2-delta receptor normally has very low expression, but increases dramatically at the onset of puberty in the part of the brain that regulates emotion. Paradoxically, THP reduced the inhibition produced by these alpha4-beta2-delta GABA-A receptors, increasing brain activity to produce a state of increased anxiety. Stress also increased anxiety at puberty, due to the paradoxical effects of this hormone that is released by stress.

Dr. Smith and colleagues identified the site on human recombinant alpha4-beta2-delta GABA-A receptors that produced the anxiety respo
'"/>

Contact: Sheryl S. Smith
sheryl.smith@downstate.edu
516-353-4714
SUNY Downstate Medical Center
11-Mar-2007


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: